Q-omics provides the consensus-scored BCAS2P3 profile across patient tissues and cancer cell-line models. BCAS2P3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, BCAS2P3 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, BCAS2P3 RNA expression shows 5,648 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LUSC, and STAD as cancer lineages where BCAS2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAS2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAS2P3 survival associations across molecular data types. BCAS2P3 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAS2P3 RNA expression–survival associations across cancer types. High BCAS2P3 expression shows unfavorable associations in BRCA, STAD, LAML, HNSC and MESO, but favorable associations in ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for BCAS2P3 RNA expression.
This table summarizes BCAS2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BCAS2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAS2P3 shows lower tumor expression in LUSC. The LUSC box plot shows higher BCAS2P3 RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p < 0.001).
This table shows molecular features associated with BCAS2P3 in patient tissues and cancer cell lines. In patient samples, BCAS2P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
